Comparative in vitro activities of sparfloxacin (CI-978; AT-4140) and other antimicrobial agents against staphylococci, enterococci, and respiratory tract pathogens.
作者信息
Simor A E, Fuller S A, Low D E
机构信息
Department of Microbiology, Mount Sinai Hospital, University of Toronto, Ontario, Canada.
出版信息
Antimicrob Agents Chemother. 1990 Nov;34(11):2283-6. doi: 10.1128/AAC.34.11.2283.
Abstract
The in vitro activity of sparfloxacin (CI-978; AT-4140) was compared with those of other antimicrobial agents against isolates of staphylococci, enterococci, and various respiratory tract pathogens. Sparfloxacin was the most active drug tested against staphylococci (MIC for 90% of the strains tested [MIC90], 0.125 micrograms/ml) and enterococci (MIC90, 1.0 microgram/ml). It was also active against Haemophilus influenzae (MIC90, less than or equal to 0.06 microgram/ml), Moraxella (Branhamella) catarrhalis (MIC90, 0.125 microgram/ml), Streptococcus pneumoniae (MIC90, 0.5 microgram/ml), and Streptococcus pyogenes (MIC90, 1.0 microgram/ml).
摘要
相似文献
1
Comparative in vitro activities of sparfloxacin (CI-978; AT-4140) and other antimicrobial agents against staphylococci, enterococci, and respiratory tract pathogens.
Antimicrob Agents Chemother. 1990 Nov;34(11):2283-6. doi: 10.1128/AAC.34.11.2283.
2
Comparative in vitro assessment of sparfloxacin activity and spectrum using results from over 14,000 pathogens isolated at 190 medical centers in the USA. SPAR Study Group.
Diagn Microbiol Infect Dis. 1997 Nov;29(3):173-86. doi: 10.1016/s0732-8893(97)81807-x.
3
Sensitivity to sparfloxacin and other antibiotics, of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis strains isolated from adult patients with community-acquired lower respiratory tract infections: a European multicentre study. SPAR Study Group. Surveillance Programme of Antibiotic Resistance.
J Antimicrob Chemother. 1998 Feb;41(2):207-14. doi: 10.1093/jac/41.2.207.
4
In vitro evaluation of sparfloxacin activity and spectrum against 24,940 pathogens isolated in the United States and Canada, the final analysis.
Diagn Microbiol Infect Dis. 1998 May;31(1):313-25. doi: 10.1016/s0732-8893(97)00247-2.
5
Activities and postantibiotic effects of gemifloxacin compared to those of 11 other agents against Haemophilus influenzae and Moraxella catarrhalis.
Antimicrob Agents Chemother. 2000 Mar;44(3):633-9. doi: 10.1128/AAC.44.3.633-639.2000.
6
BAY 12-8039, a novel fluoroquinolone. Activity against important respiratory tract pathogens.
Diagn Microbiol Infect Dis. 1998 Sep;32(1):45-50. doi: 10.1016/s0732-8893(98)00042-x.
7
In vitro activity of sparfloxacin (AT-4140 and CI-978), a new quinolone antimicrobial agent, against Haemophilus and gram-positive cocci.
Diagn Microbiol Infect Dis. 1991 Jul-Aug;14(4):355-60. doi: 10.1016/0732-8893(91)90028-e.
8
Moxifloxacin sensitivity of respiratory pathogens in the United Kingdom.
J Chemother. 2002 Feb;14(1):19-24. doi: 10.1179/joc.2002.14.1.19.
9
[National multicenter study of the in vitro activity of moxifloxacin against respiratory tract pathogens. Spanish Study Group on Moxifloxacin].
Rev Esp Quimioter. 2000 Mar;13(1):37-43.
10
In vitro activity of the novel ketolide HMR 3647 and comparative oral antibiotics against Canadian respiratory tract isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.
Diagn Microbiol Infect Dis. 1999 Sep;35(1):37-44. doi: 10.1016/s0732-8893(99)00053-x.
引用本文的文献
1
Sparfloxacin. A review of its antibacterial activity, pharmacokinetic properties, clinical efficacy and tolerability in lower respiratory tract infections.
Drugs. 1997 Apr;53(4):700-25. doi: 10.2165/00003495-199753040-00010.
2
Pharmacokinetics of sparfloxacin and serum bactericidal activity against pneumococci.
Antimicrob Agents Chemother. 1996 Mar;40(3):776-9. doi: 10.1128/AAC.40.3.776.
3
Multiple-dose pharmacokinetics of sparfloxacin and its influence on fecal flora.
Antimicrob Agents Chemother. 1994 Mar;38(3):455-9. doi: 10.1128/AAC.38.3.455.
4
New quinolones and gram-positive bacteria.
Antimicrob Agents Chemother. 1994 Feb;38(2):163-9. doi: 10.1128/AAC.38.2.163.
5
Suggested modifications for disk diffusion susceptibility testing criteria for levofloxacin and sparfloxacin following tests with a predictor panel of ciprofloxacin-resistant clinical isolates.
J Clin Microbiol. 1995 Jan;33(1):146-8. doi: 10.1128/jcm.33.1.146-148.1995.
6
In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin.
Antimicrob Agents Chemother. 1991 May;35(5):955-60. doi: 10.1128/AAC.35.5.955.
7
Lomefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
Drugs. 1991 Dec;42(6):1018-60. doi: 10.2165/00003495-199142060-00009.
8
Future directions in antimicrobial chemotherapy.
Pharm Weekbl Sci. 1992 Aug 21;14(4A):229-44. doi: 10.1007/BF01962545.
9
In vitro activity of sparfloxacin compared with those of five other quinolones.
Antimicrob Agents Chemother. 1992 Mar;36(3):558-65. doi: 10.1128/AAC.36.3.558.
10
In vitro activity of sparfloxacin and three other fluoroquinolones against methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis.
Eur J Clin Microbiol Infect Dis. 1992 Jan;11(1):55-8. doi: 10.1007/BF01971273.
本文引用的文献
1
Treatment of skin and soft tissue infections with oral ciprofloxacin.
J Antimicrob Chemother. 1986 Nov;18 Suppl D:153-7. doi: 10.1093/jac/18.supplement_d.153.
2
Treatment of bone, joint, and soft-tissue infections with oral ciprofloxacin.
Antimicrob Agents Chemother. 1987 Feb;31(2):151-5. doi: 10.1128/AAC.31.2.151.
3
Ciprofloxacin for eradication of methicillin-resistant Staphylococcus aureus colonization.
Am J Med. 1987 Apr 27;82(4A):215-9.
4
Single-dose ciprofloxacin at 100 versus 250 mg for treatment of uncomplicated urinary tract infections in women.
Antimicrob Agents Chemother. 1987 Feb;31(2):354-6. doi: 10.1128/AAC.31.2.354.
5
Preliminary evaluation of ciprofloxacin, a new 4-quinolone antibiotic, in the treatment of febrile neutropenic patients.
J Antimicrob Chemother. 1986 Nov;18 Suppl D:165-74. doi: 10.1093/jac/18.supplement_d.165.
6
The comparative in-vitro activity of eight newer quinolones and nalidixic acid.
J Antimicrob Chemother. 1986 Nov;18 Suppl D:1-20. doi: 10.1093/jac/18.supplement_d.1.
7
In vitro activities of PD 117,596 and reference antibiotics against 448 clinical bacterial strains.
Antimicrob Agents Chemother. 1988 Sep;32(9):1450-5. doi: 10.1128/AAC.32.9.1450.
8
The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro.
Antimicrob Agents Chemother. 1985 Oct;28(4):581-6. doi: 10.1128/AAC.28.4.581.
9
In-vitro activity of newer quinolones against aerobic bacteria.
J Antimicrob Chemother. 1986 Apr;17 Suppl B:29-39. doi: 10.1093/jac/17.suppl_b.29.
10
The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.
Antimicrob Agents Chemother. 1985 Nov;28(5):716-21. doi: 10.1128/AAC.28.5.716.
Zotero 插件